EU drug regulator: Uncommon blood clot ‘very uncommon AstraZeneca facet impact’

The regulator stated that one believable clarification for the mixture of blood clots and low blood platelets was an “immune response, resulting in a situation much like one seen typically in sufferers handled with heparin (heparin induced thrombocytopenia, HIT)”.